Tag Archives: AReSVi-006

GSK’s Arexvy RSV Vaccine Approved in Japan for Adults Aged 60 and Above, a First for the Country

(IN BRIEF) GSK plc has received approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) for its Arexvy (respiratory syncytial virus vaccine, recombinant adjuvanted) to prevent respiratory syncytial virus (RSV) disease in adults aged 60 and above. This marks … Read the full press release